Treating Bipolar 1 Disorder
Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder
SOURCE: Alkermes
DESCRIPTION:
Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq
About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
KEYWORDS: NASDAQ: ALKS, Alkermes
![]()
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View MoreRecent Quotes
View MoreQuotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.